Skip to main content

Table 1 Patient characteristics

From: Mediating effects of self-stigma and depression on the association between autistic symptoms and recovery in patients with schizophrenia-spectrum disorders: a cross-sectional study

 

Total samples (N = 105)

Outpatients (N = 55, 52.3%)

Inpatients (N = 50, 47.7%)

p-value

Sex (male/female)a

48/57

22/33

26/24

0.244

Age (mean ± SD) b

47.0 ± 13.3

47.8 ± 14.2

46.1 ± 12.4

0.529

Diagnosisa

 Schizophrenia

103

54

48

1

 Schizoaffective disorder

2

0

2

 

 Delusional disorder

1

1

0

 

 Age of onset (mean ± SD) b

28.8 ± 11.5

30.2 ± 11.7

27.3 ± 11.1

0.156

 Duration of hospitalization (at time of assessment, mean ± SD, days)

53.0 ± 66.0

 

53.0 ± 66.0

 

 Number of hospitalizations b

4.0 ± 5.1

3.5 ± 4.7

4.7 ± 5.5

0.528

Years of educationa

0.912

  ≤ 9

36

18

18

 

  > 9- ≤ 12

36

20

16

 

  > 12

32

17

15

 

Marital statea

 Single

71

34

37

0.372

 Married

20

13

7

 

 Divorced

14

8

6

 

 Widow

1

1

0

 

Partnersa

 Yes

84

45

39

0.635

 No

21

10

11

 

 Antipsychotic medicationb

Antipsychotic dose

(SGA + FGA) (CP equivalent, mean ± SD, mg/day)

617.2 ± 349.9

558.1 ± 360.0

682.2 ± 323.0

0.67

 Antipsychotic dose of SGA (CP equivalent, mean ± SD, mg/day)

582.8 ± 337.5

533.2 ± 352.8

637.4 ± 316.7

0.114

 Antipsychotic dose of FGA (CP equivalent, mean ± SD, mg/day)

34.9 ± 108.23

24.9 ± 84.6

44.8 ± 129.5

0.351

  1. a Fisher’s exact test p-value for the difference in sex, diagnosis, years of education, marital status, and partners between the two groups
  2. b Unpaired t-test p-value for the difference in age between the two groups
  3. AQ Autism-Spectrum Quotient, CP Chlorpromazine, FGA First-generation antipsychotics, IMSI Internalized Stigma of Mental Illness, QIDS, Quick Inventory of Depressive Symptomatology, RAS Recovery Assessment Scale, SGA Second-generation antipsychotics